Phase III Development of Laquinimod Progressing - Patient Enrolment Completed

On June 25, 2009, Teva Pharmaceutical (TEVA) and its development partner, Active Biotech announced that they have finished enrolling patients for a second pivotal phase III clinical study, BRAVO, which is being conducted to evaluate the novel, oral once-daily immunomodulating compound, laquinimod, for the treatment of relapsing-remitting multiple sclerosis (RRMS).

Multiple sclerosis is a nervous system disease that affects the brain, spinal cord and optic nerves. BRAVO will study the efficacy, safety and tolerability of laquinimod versus placebo. The trial has also been designed to provide risk-benefit data for laquinimod versus Avonex, a currently available injectable treatment.

The BRAVO study is being conducted with more than 1200 patients at 156 sites across the U.S., Europe, Israel and South Africa. Another phase III study, ALLEGRO, is currently ongoing in North America, Europe and Asia.